Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: A patterns of care study

Eifel, Patricia J.; Moughan, Jennifer; Erickson, Beth; Iarocci, Tom; Grant, Donald L.; Owen, Jean B.

doi:10.1016/j.ijrobp.2004.04.063

Cited by 117 publications

(70 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Undoubtedly, the biggest advance has come from combining chemotherapy concomitantly with radiotherapy. The publication of five large trials, each showing a benefit associated with cisplatin-based chemoradiotherapy, prompted a rare NCI alert that has led to dramatic and widespread uptake of concomitant chemoradiotherapy in practice, as either definitive or adjuvant therapy [46]; [47]; [48]; [49].…”

Section: Discussionmentioning

confidence: 99%

“…Cisplatin is the most commonly used drug [46]; [48], usually administered weekly [48], as a single agent [48] [49], and this is supported by the evidence to date [16]; [17]; [21]. In addition, the use of chemoradiotherapy based on cisplatin combinations [49]; [49]; [46], non-platinum drugs, such as 5-FU, or non-platinum combinations [49] also seems reasonably evidencebased [21].…”

Section: Discussionmentioning

confidence: 99%

“…In addition, the use of chemoradiotherapy based on cisplatin combinations [49]; [49]; [46], non-platinum drugs, such as 5-FU, or non-platinum combinations [49] also seems reasonably evidencebased [21]. One randomised trial directly comparing cisplatin with 5FU-based chemoradiotherapy closed early after interim analyses showed higher rates of progression with 5-FU [50], but was no longer powered to detect a difference in progression-free or overall survival, and so is inconclusive in this regard.…”

Section: Discussionmentioning

confidence: 99%

“…One randomised trial directly comparing cisplatin with 5FU-based chemoradiotherapy closed early after interim analyses showed higher rates of progression with 5-FU [50], but was no longer powered to detect a difference in progression-free or overall survival, and so is inconclusive in this regard. The use of hydoxyurea as single agent in practice [46] is not adequately supported by the older trials [9], but emerging trial evidence may counter this view [26].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Concomitant and Neoadjuvant Chemotherapy for Cervical Cancer

Tierney¹,

Vale²,

Symonds³

2008

Clinical Oncology

View full text Add to dashboard Cite

In the past, women with early stage cervical cancer have been treated with radical radiotherapy or radical surgery, and women with locally advanced disease with radical radiotherapy, each offering a good chance of cure. Numerous trials have investigated whether giving cytotoxic chemotherapy alongside radiotherapy or prior to local treatment could augment the established benefits of these therapies, and are reviewed here. There is a strong basis for the use of platinum-based chemoradiotherapy, the current standard of care, but little convincing evidence as to the therapeutic benefits of using concomitant hydroxyurea. Chemoradiotherapy based on other non-platinum agents may offer alternatives. The effect of chemoradiotherapy appears to vary according to the stage of disease, but all types of women benefit. Neoadjuvant chemotherapy prior to radiotherapy could jeopardise survival and should be avoided unless perhaps a 'quick', dose intense regimen is used. Neoadjuvant chemotherapy before surgery may be beneficial, but the approach will remain controversial until it is tested against platinum-based chemoradiotherapy. Future studies many include combinations of other cytotoxics such as topotecan with cisplatin-based concomitant chemoradiotherapy or the addition of agents targeted against specific receptors such as EGFR.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Concomitant and Neoadjuvant Chemotherapy for Cervical Cancer

Tierney¹,

Vale²,

Symonds³

2008

Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Published PCS reports had an impact on the clinical management of cancers of cervix, breast, and head and neck etc. (Shikama et al, 2003;Eifel et al, 2004;Ang et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Clinical Audit in Radiation Oncology: Results from One Academic Centre in Delhi, India

Kaur

Mohanti²,

Muzumder³

2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The objective was to analyze the radiotherapy (RT) practice at the cancer centre of a tertiary academic medical institution in Delhi. This audit from an Indian public institution covered patient care processes related to cancer diagnosis, integration of RT with other anti-cancer modalities, waiting time, overall treatment time, and compliance with RT. Over a period of one year, all consecutively registered patients in radiotherapy were analyzed for the audit cycle. Analysis of 1,030 patients showed median age of 49.6 years, with presentation as stage I and II in 14.2%, stage III and IV in 71.2% and unknown stage in 14.6%. A total of 974 (95%) were advised for RT appointment; 669 (68.6%) for curative intent and 31.4% for palliation. Mean times for diagnostic workup and from registration at cancer centre to radiotherapy referral were 33 and 31 days respectively. Median waiting time to start of RT course was 41 days. Overall RT compliance was 75% and overall duration for a curative RT course ranged from 50 days to 61 days. Non-completion and interruption of RT course were observed in 12% and 13% respectively. Radiotherapy machine burden in a public cancer hospital in India increases the waiting time and 25% of advised patients do not comply with the prescribed treatment. Infrastructure, machine and manpower constraints lead to more patients being treated on cobalt (74%) and by two-dimensional (78%) techniques.

show abstract

Current controversies in high‐dose‐rate versus low‐dose‐rate brachytherapy for cervical cancer

Stewart¹,

Viswanathan²

2006

Cancer

View full text Add to dashboard Cite

The use of brachytherapy in the treatment of cervical cancer has increased worldwide since its initial introduction over 100 years ago. However, certain aspects of the use of high-dose-rate (HDR) versus low-dose-rate (LDR) brachytherapy continue to be controversial, particularly the role of HDR in FIGO Stage III cervical cancer and the use of HDR with concurrent chemotherapy. This study represents a systematic literature review of prospective and retrospective series of patients with cervical carcinoma treated with external-beam radiation

show abstract

Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: A patterns of care study

Cited by 117 publications

References 14 publications

Concomitant and Neoadjuvant Chemotherapy for Cervical Cancer

Concomitant and Neoadjuvant Chemotherapy for Cervical Cancer

Clinical Audit in Radiation Oncology: Results from One Academic Centre in Delhi, India

Current controversies in high‐dose‐rate versus low‐dose‐rate brachytherapy for cervical cancer

Contact Info

Product

Resources

About